News
FDA Approves First Twice-a-Year HIV Prevention Shot
Made by Gilead Sciences and sold under the name Yeztugo, the drug gives people a new way to stay protected from HIV without needing daily pills or frequent injections, The New York Times reported. “We’re on the precipice of now being able to deliver the greatest prevention option we’ve had in 44 years of this epidemic,
KTVU FOX 2 on MSN2d
New HIV prevention drug introduced, but it comes at a high costAs with many chronic and often deadly diseases, an ounce of prevention can be worth a ton of cure. It's a breakthrough drug ...
The US FDA has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that offers near-complete protection with just two injections per year. Despite its potential, concerns about high ...
A drug currently used to treat ... effectively reducing the risk of HIV infection by 96% and proving 89% more effective than Truvada, a pill taken once a day. The trial was unblinded early ...
There’s no cure for HIV or AIDS, but medication slows down virus growth. Most people who take the medication correctly can live a long, healthy life. Single-pill regimens are helpful because ...
The FDA approved a single-pill, two-drug regimen for adolescents with HIV. Image: Adobe Stock Dovato, which contains the drugs dolutegravir and lamivudine, was already approved for ART-naive ...
The Blue Cross Blue Shield of North Carolina campus on University Drive in Durham, N.C. on Friday, January 6, 2023. Robert Willett rwillett@newsobserver.com Thousands of North Carolina residents ...
However there was a rise of 17% in new HIV diagnoses in the capital. The treatment which has been free on the NHS in England since 2020, involves taking the PrEP pill containing the drugs ...
June 20 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday a late-stage study showed its long-acting injectable drug ... HIV infection in women compared to its existing daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback